Did the Company Violate FCA By Promoting an Off-Label Use of Botox? The Court Did Not Think So
The relator alleged the company violated the Anti-Kickback Statute and submitted false claims to Medicaid under the FCA by promoting off-label use of Botox.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every case digest, six days a week.
$750/year